Sign inJoin waitlistJoin the waitlist

Brian Orr

| Associate Professor, Oncology Division, Oncology Fellowship Director · Medical University of South Carolina College of Medicine

Credentials: · · · · · ·

History

| Associate Professor, Oncology Division, Oncology Fellowship · Medical University of South Carolina College of Medicine
Present
Medical University of South Carolina College of Medicine
Present
Medical University of South Carolina College of Medicine
Present

University of Pittsburgh
2015–2018
Obstetrics and Gynecology
University of South Florida Morsani College of Medicine
2011–2015
University of Tennessee College of Medicine
2006–2010

Research

Diagnosis and Treatment of Ovarian Cancer
Review · Hematology/Oncology Clinics of North America · 2018 · First of 2 authors · 228 citations
Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer
JCI Insight · 2020 · 181 citations
BAD-mediated apoptotic pathway is associated with human cancer development
International Journal of Molecular Medicine · 2015 · 46 citations

Robert Edwards
13 papers
ST
Sarah Taylor
13 papers
JV
John Vargo
8 papers
Madeleine Courtney-Brooks
8 papers
Sushil Beriwal
8 papers
AO
Alexander Olawaiye
7 papers
JB
Jessica Berger
7 papers
Paniti Sukumvanich
7 papers
Michelle Boisen
6 papers · 1 as a fellow
Gweneth Lazenby
4 papers
JL
Jamie Lesnock
3 papers
JC
John Comerci
3 papers

Clinical trials

Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab
Principal investigator · Not yet recruiting · Phase 2
Medical University of South Carolina
2026–2032
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Site PI · Recruiting · Phase 3
GOG Foundation
2024–2034